3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
9
Unknown
3
Recruiting
2
Not yet recruiting
2
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
1
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Carcinoma, Hepatocellular
8
Nasopharyngeal Carcinoma
6
Esophageal Neoplasms
6
Neoplasm Metastasis
5
Triple Negative Breast Neoplasms
4
Stomach Neoplasms
4
Melanoma
4
Advanced NSCLC
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Rectal Neoplasms
3
Pancreatic Neoplasms
3
Small Cell Lung Carcinoma
2
Sarcoma
2
Neoplasms
2
Lung Neoplasms
2
Locally Advanced Rectal Cancer
2
Leukemia, Myeloid, Acute
2
Esophageal Squamous Cell Carcinoma
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Biliary Tract Neoplasms
2
Advanced Solid Tumors
2
Advanced Solid Tumor
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Interventions
pembrolizumab
38
Blood Specimen Collection
38
Bevacizumab
22
Surveys and Questionnaires
18
Standard of Care
18
Radiotherapy
17
Exercise
17
Carboplatin
17
Nivolumab
15
atezolizumab
14
Paclitaxel
14
Cisplatin
14
Drug Therapy
13
Fluorouracil
12
Cyclophosphamide
12
Cetuximab
11
Trastuzumab
10
Pemetrexed
10
Leucovorin
10
Docetaxel
10
Dexamethasone
10
Oxaliplatin
9
Biopsy
9
pertuzumab
8
olaparib
8
Temozolomide
8
Panitumumab
8
Observation
8
Irinotecan
8
abemaciclib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms
×
Immune Checkpoint Inhibitors
×
Clear all
NCT06524570
2026-02-18
iFOCUS
UMC Utrecht
Phase 1
Recruiting
24 enrolled
NCT04673942
2024-10-26
BETA-PRIME
EpicentRx, Inc.
Phase 2
Recruiting
140 enrolled